What is BioScale?
BioScale operates as a high-complexity CLIA laboratory, specializing in the intricate field of protein assay development and testing. The company's expertise extends to providing comprehensive, end-to-end immuno/protein assay solutions, catering to a diverse clientele that includes hospital and medical centers, biotechnology firms, pharmaceutical companies, and diagnostic testing businesses. A key offering is the FDA-cleared Presage ST2 Assay, vital for chronic heart failure prognosis. BioScale's seasoned team is dedicated to delivering high-quality protein biomarker data, supporting advanced research and clinical testing needs across various therapeutic areas and specimen types.
How much funding has BioScale raised?
BioScale has raised a total of $116.2M across 5 funding rounds:
Series B
$3M
Series C
$20.7M
Series D
$25M
Unspecified
$18.8M
Series A
$48.7M
Series B (2005): $3M, investors not publicly disclosed
Series C (2007): $20.7M led by F2 Ventures and Blackfin Technology
Series D (2010): $25M, investors not publicly disclosed
Unspecified (2013): $18.8M featuring WFD VENTURES, Morningside Group, and New Science Ventures
Series A (2013): $48.7M backed by New Science Ventures newscienceventures.com and Morningside Ventures morningside.com
Key Investors in BioScale
F2 Ventures
F2 Ventures is a healthcare investment platform focused on arbitrage opportunities across the biotech sector, targeting innovation at the right stage for maximum impact.
New Science Ventures
New Science Ventures, LLC (NSV) is a venture capital firm based in Connecticut and London that invests in early and late-stage companies utilizing novel scientific approaches in the life sciences and information technology sectors. The firm focuses on addressing significant unmet needs within these industries.
WFD VENTURES
WFD Ventures LLC provides equity financing and industry expertise to medical device and healthcare technology companies. The principals of WFD have extensive experience commercializing medical technologies and seek partnerships with entrepreneurs, doctors and scientists to improve medical outcomes and maximize the financial potentials of their innovations.
What's next for BioScale?
The substantial enterprise-level funding and recent strategic investment position BioScale for accelerated growth and innovation. This capital infusion is expected to fuel advancements in their protein assay development pipeline, potentially leading to new diagnostic tools and expanded testing services. The company's focus on high-complexity CLIA laboratory operations and its established relationships within the biotech, pharma, and healthcare sectors suggest a strategic expansion into new markets or the enhancement of existing service offerings. BioScale's trajectory indicates a strong commitment to addressing unmet needs in disease prognosis and biomarker discovery.
See full BioScale company page
